Plastic, Rubber, Polymer
Do you have questions?
We unleash your business potential by maximize the business innovation.
Send EmailLidocaine, Xylocaine, Lignocaine, Maricaine, Ligoncaine, Lidocaine Hydrochloride, Lidocaine HCl, 137-58-6, 6108-05-0, 73-78-9
LIDOCAINE
SECTION 1: PRODUCT IDENTITY AND CHEMICAL IDENTIFICATION
| Parameter | Lidocaine (Base) | Lidocaine Hydrochloride |
|---|---|---|
| Chemical Name (IUPAC) | 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide | 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride |
| Synonyms (Turkish) | Lidokain, Lignokain, Ksilokain | Lidokain HCl, Lignokain Hidroklorür |
| Synonyms (English) | Lidocaine, Xylocaine, Lignocaine, Maricaine, Ligoncaine | Lidocaine Hydrochloride, Xylocaine Hydrochloride |
| CAS Number | 137-58-6 | 6108-05-0 (dihydrate) / 73-78-9 (anhydrous) |
| EC Number (EINECS) | 205-302-8 | 205-302-8 (same) |
| Molecular Formula | C₁₄H₂₂N₂O | C₁₄H₂₂N₂O · HCl |
| Molecular Weight | 234.34 g/mol | 270.80 g/mol |
| Chemical Class | Amide-type local anesthetic | Amide-type local anesthetic (hydrochloride salt) |
| Physical State (20°C) | Solid (crystalline powder) | Solid (crystalline powder) |
| Color | White to off-white | White to off-white |
| Odor | Odorless | Odorless |
| Taste | Bitter and numbing | Bitter and numbing |
SECTION 2: CHEMICAL STRUCTURE
CH₃
\
C
/ \
/ \
/ \
CH₃—C C—H
\ /
\ /
C—NH—C—CH₂—N(C₂H₅)₂
/ ‖
/ O
/
CH₃
Lidocaine (Base)
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
C₁₄H₂₂N₂O
HCl salt: Lidocaine Hydrochloride (C₁₄H₂₂N₂O · HCl)
Structure Description:
| Parameter | Description |
|---|---|
| Chemical Class | Amide-type local anesthetic |
| Functional Groups | Amide (-CO-NH-), tertiary amine (-N(C₂H₅)₂), dimethylphenyl ring |
| Lipophilic Part | 2,6-dimethylphenyl ring (provides anesthetic effect) |
| Hydrophilic Part | Diethylamino group (provides water solubility) |
| Linkage | Amide bond (more stable than ester bond) |
| SMILES | CCN(CC)CC(=O)NC1=C(C)C=CC=C1C |
| InChI | InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17) |
| InChI Key | HBJZPBCJNUUEHN-UHFFFAOYSA-N |
| Hydrogen Bond Donors | 1 |
| Hydrogen Bond Acceptors | 2 |
| Rotatable Bond Count | 5 |
| Polar Surface Area (PSA) | 32.3 Ų |
SECTION 3: PHYSICAL AND CHEMICAL PROPERTIES
| Property | Lidocaine (Base) | Lidocaine Hydrochloride | Test Method / Note |
|---|---|---|---|
| Appearance | White to off-white crystalline powder | White to off-white crystalline powder | Visual |
| Odor | Odorless | Odorless | Olfactometric |
| Taste | Bitter and numbing | Bitter and numbing | Sensory |
| Molecular Weight | 234.34 g/mol | 270.80 g/mol | Calculated |
| Melting Point | 66 – 69°C | 127 – 129°C | DSC / Capillary |
| Melting Point (Monohydrate) | - | 77 – 78°C | DSC |
| Boiling Point | bp₄ 180-182°C; bp₂ 159-160°C | - | Vacuum Distillation |
| Density | ~0.9944 g/cm³ (estimated) | - | Calculated |
| Refractive Index (nD) | ~1.5110 (estimated) | - | Refractometer |
| pKa (25°C, H₂O) | ~7.88 | ~7.88 | Potentiometric |
| Water Solubility | Practically insoluble | Freely soluble | General Method |
| Ethanol Solubility | Soluble (4 mg/mL) | Soluble | General Method |
| Ether Solubility | Soluble | Soluble | General Method |
| Benzene Solubility | Soluble | Soluble | General Method |
| Chloroform Solubility | Soluble | Soluble | General Method |
| Oil Solubility | Soluble | Soluble | General Method |
| pH (0.5% Solution) | - | 4.0 – 5.5 | pH Meter |
| Vapor Pressure (25°C) | 4.28 × 10⁻⁵ mmHg | - | Calculated |
| Flash Point | >150°C (solid) | >150°C (solid) | ASTM D93 |
| Stability | Stable under normal conditions | Stable under normal conditions | - |
| Hygroscopicity | Not hygroscopic | Slightly hygroscopic | - |
| Log P (Octanol/Water) | ~2.44 (lipophilic) | - | Calculated |
SECTION 4: LIDOCAINE BASE vs HYDROCHLORIDE COMPARISON
| Property | Lidocaine (Base) | Lidocaine Hydrochloride |
|---|---|---|
| Water Solubility | Low (oil-soluble) | High (water-soluble) |
| Main Application Area | Oil-based formulations (topical creams, ointments, patches) | Aqueous formulations (injectable solutions, eye drops, oral solutions) |
| Ionization at Physiological pH | Mostly non-ionized (higher lipid solubility, faster onset) | Ionized (water-soluble, more stable) |
| Tissue Penetration | High (lipophilic) | Low (hydrophilic; effective upon injection) |
| Commercial Forms | Topical creams, ointments, patches | Injectable ampoules, eye drops, oral gels, dental cartridges |
| Systemic Absorption | Limited in topical application | Rapid and complete upon injection |
SECTION 5: CHEMICAL PROPERTIES AND REACTIVITY
| Parameter | Information |
|---|---|
| Chemical Character | Amide-type local anesthetic; weak base (pKa ~7.88) |
| Stability | Stable under normal conditions; amide bond is more resistant to hydrolysis than ester bond |
| Decomposition Products (Heating) | CO, CO₂, NOx, HCl (for salt form) |
| Incompatible Materials | Strong oxidizing agents, strong acids and bases |
| Hydrolysis | Amide bond is more resistant to hydrolysis compared to ester-type anesthetics |
| Acid-Base Reaction | Forms water-soluble salts with acids (lidocaine hydrochloride) |
| Hazardous Polymerization | Does not occur |
SECTION 6: LOCAL ANESTHETICS COMPARISON
| Property | Lidocaine | Procaine | Bupivacaine | Tetracaine | Benzocaine |
|---|---|---|---|---|---|
| CAS Number | 137-58-6 | 59-46-1 | 38396-39-3 | 94-24-6 | 94-09-7 |
| Class | Amide | Ester | Amide | Ester | Ester |
| Onset of Action | Rapid (2-5 min) | Moderate (5-10 min) | Slow (5-10 min) | Slow (5-10 min) | Slow |
| Duration | Moderate (1-2 h) | Short (30-60 min) | Long (3-8 h) | Long (2-3 h) | Short |
| pKa | 7.9 | 8.9 | 8.1 | 8.5 | 2.5 |
| Maximum Dose | 4.5 mg/kg | 10 mg/kg | 2 mg/kg | 1.5 mg/kg | Topical |
| Allergy Risk | Very Low | Moderate (PABA) | Very Low | Moderate (PABA) | Low |
| Vasodilation | Yes | Yes | Yes | Yes | None |
| Primary Use | Infiltration, topical | Infiltration, dental | Epidural, spinal | Spinal, topical | Topical |
SECTION 7: PHARMACOLOGICAL PROPERTIES AND MECHANISM OF ACTION
| Property | Description |
|---|---|
| Mechanism of Action | Blocks voltage-gated sodium (Na⁺) channels, inhibiting the generation and conduction of action potentials in nerve cells. |
| Anesthetic Class | Amide-type local anesthetic. Unlike ester-type anesthetics, metabolism occurs in the liver and allergy risk is low. |
| Onset of Action | Rapid (2-5 minutes). |
| Duration of Action | Moderate (1-2 hours); can be extended to 2-4 hours with epinephrine. |
| Vasodilator Effect | Causes local vasodilation; epinephrine is added to slow absorption and prolong duration. |
| Anti-arrhythmic Effect | Class Ib anti-arrhythmic; used in the treatment of ventricular arrhythmias. |
| Topical Effect | Effective on mucosal and skin surfaces; used in spray, gel and cream forms. |
| Absorption | Rapidly absorbed from mucosal surfaces; absorption increases from damaged skin. |
| Metabolism | Hepatic metabolism via CYP3A4 and CYP1A2 enzymes. |
| Half-Life | 1.5 – 2 hours |
| Elimination | Excreted renally via urine (~90% as metabolites) |
| Protein Binding | ~60-70% |
| Volume of Distribution | ~1-2 L/kg |
SECTION 8: MAIN APPLICATION AREAS
| Application Area | Lidocaine (Base) | Lidocaine Hydrochloride |
|---|---|---|
| Dentistry | - | Local infiltration anesthesia, nerve block (2%) |
| Surgery | - | Minor surgical procedures, epidural anesthesia (1-2%) |
| Dermatological (Topical) | Topical cream, gel, spray (2-5%) | - |
| Ophthalmic | - | Eye drops (corneal anesthesia) (1-4%) |
| Cardiology | - | Ventricular arrhythmia treatment (IV: 1-1.5 mg/kg bolus) |
| Cosmetic | Laser epilation, tattoo removal (2.5-5% cream) | Local anesthesia prior to injections |
| Emergency Medicine | - | Suturing, catheterization, minor procedures (1-2%) |
| Topical (Skin) | Skin patches, analgesic ointments | Oral gels, rinses |
| Urology | - | Urethral anesthesia (2% gel) |
| ENT | - | Laryngoscopy, bronchoscopy, endoscopy (2-4% spray) |
SECTION 9: QUALITY SPECIFICATIONS (PHARMACEUTICAL GRADE - USP/EP)
| Parameter | Specification (Base) | Specification (HCl) | Test Method |
|---|---|---|---|
| Appearance | White to off-white crystalline powder | White to off-white crystalline powder | Visual |
| Odor | Odorless | Odorless | Olfactometric |
| Assay (on dried basis) | 98.0 – 101.0% | 98.0 – 101.0% | HPLC / Titrimetric |
| Melting Point | 66 – 69°C | 127 – 129°C | DSC / Capillary |
| Loss on Drying (105°C, 2 h) | ≤0.5% | ≤0.5% | Gravimetric |
| pH (0.5% Solution) | - | 4.0 – 5.5 | pH Meter |
| Chloride (Cl⁻) | - | 13.7 – 14.5% | Argentometric |
| Sulfated Ash | ≤0.1% | ≤0.1% | Gravimetric |
| Heavy Metals (as Pb) | ≤20 ppm | ≤20 ppm | ICP-MS / USP <231> |
| Lead (Pb) | ≤3 ppm | ≤3 ppm | ICP-MS |
| Arsenic (As) | ≤3 ppm | ≤3 ppm | ICP-MS |
| Mercury (Hg) | ≤1 ppm | ≤1 ppm | ICP-MS |
| Cadmium (Cd) | ≤1 ppm | ≤1 ppm | ICP-MS |
| Related Substances (Single) | ≤0.5% | ≤0.5% | HPLC |
| Related Substances (Total) | ≤1.0% | ≤1.0% | HPLC |
| 2,6-Dimethylaniline | ≤100 ppm | ≤100 ppm | HPLC |
| Total Microbial Count | ≤100 CFU/g | ≤100 CFU/g | USP <61> |
| Yeast and Mold | ≤10 CFU/g | ≤10 CFU/g | USP <61> |
| E. coli | Negative in 1g | Negative in 1g | USP <62> |
| Salmonella spp. | Negative in 25g | Negative in 25g | USP <62> |
| S. aureus | Negative in 1g | Negative in 1g | USP <62> |
| P. aeruginosa | Negative in 1g | Negative in 1g | USP <62> |
SECTION 10: TOXICOLOGICAL PROFILE
| Parameter | Value |
|---|---|
| Acute Oral Toxicity (LD50, Rat) | ~317 mg/kg |
| Acute Dermal Toxicity (LD50, Rabbit) | >2,000 mg/kg |
| Acute Inhalation Toxicity | Toxic (R23) |
| Skin Irritation | Mild irritant |
| Eye Irritation | Irritant |
| Inhalation Irritation | Inhalation of dust may cause mechanical irritation |
| Skin Sensitization | May cause sensitization (rare) |
| Carcinogenicity | Not classified (IARC, NTP) |
| Mutagenicity | Negative in in vitro tests |
| Reproductive Toxicity | Fetal effects at high doses; use with caution in pregnancy (FDA Category B) |
| Systemic Toxicity | At high doses: dizziness, tinnitus, convulsions, cardiac depression |
| Maximum Safe Dose (Adult) | 4.5 mg/kg (without epinephrine); 7 mg/kg (with epinephrine) |
| NOAEL (Rat, 90 days) | ~50 mg/kg/day |
| Target Organs | Nervous system, heart, liver |
SECTION 11: GHS CLASSIFICATION AND LABELING
GHS Classification (in accordance with 1272/2008/EC):
| Hazard Class | Category | H-Statement |
|---|---|---|
| Acute Toxicity (Oral) | Category 3 | H301 |
| Acute Toxicity (Dermal) | Category 3 | H311 |
| Acute Toxicity (Inhalation) | Category 3 | H331 |
| Skin Irritation | Category 2 | H315 |
| Eye Irritation | Category 2 | H319 |
| STOT - SE | Category 3 | H335 |
Signal Word: DANGER
Hazard Pictograms: GHS06 (Skull and Crossbones)
Hazard Statements (H-Codes):
| Code | Statement |
|---|---|
| H301 | Toxic if swallowed |
| H311 | Toxic in contact with skin |
| H315 | Causes skin irritation |
| H319 | Causes serious eye irritation |
| H331 | Toxic if inhaled |
| H335 | May cause respiratory irritation |
NFPA 704 Hazard Classification:
| Health | Flammability | Reactivity | Special |
|---|---|---|---|
| 2 | 0 | 0 | - |
| (Moderate health hazard) | (Non-combustible) | (Stable) | (None) |
SECTION 12: PRECAUTIONARY STATEMENTS (P-CODES)
| Code | Statement |
|---|---|
| P261 | Avoid breathing dust/fume/gas |
| P264 | Wash hands thoroughly after handling |
| P270 | Do not eat, drink or smoke when using this product |
| P271 | Use only outdoors or in a well-ventilated area |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection |
| P301+P310 | IF SWALLOWED: Immediately call a POISON CENTER/doctor |
| P302+P352 | IF ON SKIN: Wash with plenty of soap and water |
| P304+P340 | IF INHALED: Remove person to fresh air and keep comfortable for breathing |
| P305+P351+P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and continue rinsing |
| P311 | Call a POISON CENTER/doctor |
| P321 | Specific treatment (see label instructions) |
| P330 | Rinse mouth |
| P332+P313 | If skin irritation occurs: Get medical advice/attention |
| P337+P313 | If eye irritation persists: Get medical advice/attention |
| P362+P364 | Take off contaminated clothing and wash it before reuse |
| P403+P233 | Store in a well-ventilated place. Keep container tightly closed |
| P405 | Store locked up |
| P501 | Dispose of contents/container in accordance with local/regional/national/international regulations |
SECTION 13: FIRST AID MEASURES
| Route of Exposure | Action |
|---|---|
| Inhalation | Remove to fresh air immediately. Get medical attention if respiratory difficulty persists. If breathing has stopped, perform artificial respiration. |
| Skin Contact | Remove contaminated clothing immediately. Wash with plenty of soap and water for at least 15 minutes. Get medical attention. |
| Eye Contact | Rinse immediately with plenty of water for at least 15 minutes. Keep eyelids open. Remove contact lenses if present. Get immediate medical attention. |
| Ingestion | Rinse mouth with water. Do NOT induce vomiting. Get immediate medical attention and show the container or label. |
| Systemic Toxicity Symptoms | Dizziness, tinnitus, numbness around the mouth, confusion, muscle twitching, convulsions, loss of consciousness, respiratory depression, cardiac arrhythmia. If these symptoms occur, seek immediate medical attention. |
| Note to Physician | Toxicity management: Benzodiazepines (diazepam) for convulsions; atropine and epinephrine for cardiac depression. No specific antidote. |
SECTION 14: FIREFIGHTING MEASURES
| Parameter | Information |
|---|---|
| Fire Hazard | Combustible (solution forms are highly flammable) |
| Flash Point | 9°C (in solution form) |
| Fire-Related Hazards | CO, CO₂, NOx, HCl (for salt form) |
| Suitable Extinguishing Media | Water mist, CO₂, dry chemical powder, alcohol-resistant foam |
| Unsuitable Extinguishing Media | Water jet (may spread burning material) |
| Special Protective Equipment | Self-contained breathing apparatus (SCBA), full protective clothing |
| Special Precautions | Prevent firefighting water from entering water bodies. Avoid dust cloud formation. |
SECTION 15: STORAGE AND SHELF LIFE
| Parameter | Information |
|---|---|
| Storage Conditions | Room temperature (15-25°C), dry, well-ventilated area, light-protected containers. |
| Temperature Limits | 15-25°C (ideal); do not exceed 30°C |
| Humidity | Low humidity environment (especially for HCl salt) |
| Light | Light-proof containers (amber glass, HDPE, aluminum) |
| Container Requirements | Tightly closed, light-proof, moisture-resistant containers |
| Incompatible Materials | Strong oxidizing agents, ignition sources, moisture (for HCl salt) |
| Shelf Life | 36-60 months (unopened original packaging, under proper storage conditions) |
| Signs of Degradation | Color change (yellowing), caking, odor change, HPLC impurity increase |
| Stability Note | Stable under normal conditions; amide bond is more stable than ester anesthetics |
SECTION 16: PACKAGING OPTIONS
| Packaging Type | Quantity | Material | Application Area |
|---|---|---|---|
| Aluminum Foil Bag | 1 kg, 5 kg | Laminated aluminum / PE (light and moisture proof) | High purity, pharmaceutical |
| Fiber Drum (PE Lined) | 25 kg | Cardboard + PE liner | Industrial supply |
| HDPE Drum | 25 kg, 50 kg | HDPE (opaque, moisture barrier) | Pharmaceutical manufacturing |
| Amber Glass Bottle | 100 g, 500 g, 1 kg | Amber glass (UV protected) | Laboratory, analytical standards |
| Kraft Bag (PE Lined) | 10 kg, 25 kg | Kraft paper / PE liner | Economical packaging |
| IBC Container | 500 kg, 1000 kg | UV-protected HDPE | Large-scale industrial supply |
SECTION 17: TRANSPORTATION INFORMATION
| Parameter | Information |
|---|---|
| UN Number | UN 3249 (Toxic Solid, Organic, N.O.S.) |
| Hazard Class | 6.1(b) (Toxic Substances) |
| Packing Group | III |
| ADR/RID | UN 3249, Toxic Solid, 6.1, PG III |
| IMDG Code | UN 3249, Toxic Solid, 6.1, PG III |
| IATA (Air) | UN 3249, Toxic Solid, 6.1, PG III |
| Marine Pollutant | No |
| Transport Temperature | Ambient temperature |
| Transport Precautions | Keep away from heat sources, ignition sources and oxidizing agents. Light-proof packaging. |
| Spill Cleanup | Avoid dust generation. Collect mechanically. Clean with absorbent material. Do not allow to enter sewers or water bodies. |
SECTION 18: REGULATORY STATUS
| Region / Authority | Status |
|---|---|
| USA (USP-NF) | Official monograph (USP Lidocaine; Lidocaine Hydrochloride) |
| European Pharmacopoeia | Official monograph (Ph. Eur. Lidocaine; Lidocaine Hydrochloride) |
| USA (FDA) | Prescription drug; OTC topical forms approved |
| WHO Essential Medicines List | Essential medicine (local anesthetic and anti-arrhythmic) |
| Turkey | Licensed pharmaceutical active ingredient; prescription drug; KKDIK registered |
| REACH (EU) | Registered substance |
| TSCA (USA) | Listed |
| DEA / Controlled Substance | Not a controlled substance |
| IARC | Not classified (not carcinogenic) |
| NTP | Not listed |
| OSHA | Regulated as hazardous substance |
| California (Prop 65) | Not listed |
SECTION 19: OTHER NAMES AND SYNONYMS
| Type | Name |
|---|---|
| Chemical Names | 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-(Diethylamino)-2',6'-acetoxylidide |
| Common Names (Turkish) | Lidokain, Lignokain, Ksilokain |
| Common Names (English) | Lidocaine, Xylocaine, Lignocaine, Maricaine, Ligoncaine |
| Salt Form | Lidocaine Hydrochloride (CAS 73-78-9 / 6108-05-0) |
| CAS Number (Base) | 137-58-6 |
| CAS Number (HCl) | 6108-05-0 (dihydrate) / 73-78-9 (anhydrous) |
| EC Number | 205-302-8 |
| HS Code | 2924.29 |
SECTION 20: SUMMARY TABLE
| Parameter | Lidocaine (Base) | Lidocaine Hydrochloride |
|---|---|---|
| CAS Number | 137-58-6 | 6108-05-0 / 73-78-9 |
| Molecular Formula | C₁₄H₂₂N₂O | C₁₄H₂₂N₂O · HCl |
| Molecular Weight | 234.34 g/mol | 270.80 g/mol |
| Appearance | White to off-white crystalline powder | White to off-white crystalline powder |
| Melting Point | 66 – 69°C | 127 – 129°C |
| Water Solubility | Practically insoluble | Freely soluble |
| pKa | ~7.88 | ~7.88 |
| Primary Function | Amide-type local anesthetic; Class Ib anti-arrhythmic | Amide-type local anesthetic; Class Ib anti-arrhythmic |
| Main Application | Oil-based topical formulations | Aqueous formulations (injection, eye drops) |
| Shelf Life | 36-60 months | 36-60 months |
| GHS Signal Word | DANGER | DANGER |
| UN Number | UN 3249 | UN 3249 |
| Hazard Class | 6.1(b) | 6.1(b) |
SECTION 21: CRITICAL WARNINGS AND BEST PRACTICES
CRITICAL WARNINGS:
-
Systemic Toxicity: High doses or intravascular injection can cause serious cardiac and neurological toxicity. Maximum dose must not be exceeded.
-
Dose Calculation: Maximum adult dose is 4.5 mg/kg (without epinephrine) and 7 mg/kg (with epinephrine). Pediatric doses should be adjusted.
-
Allergy: As an amide-type anesthetic, there is no cross-allergy risk with ester-type anesthetics (procaine, benzocaine). However, caution should be exercised if there is any history of allergy.
-
Aspiration: Always aspirate before injection; avoid intravascular injection.
-
Flammable Solution: Solution forms are highly flammable; keep away from ignition sources.
-
Pregnancy: FDA Category B; use during pregnancy only if clearly necessary.
-
Topical Use: Rapidly absorbed from mucous membranes and damaged skin; calculate total dose when applying to large surfaces.
BEST PRACTICE RECOMMENDATIONS:
-
Correct Form Selection: Choose the correct form based on the application. Use Lidocaine Hydrochloride for aqueous solutions and Lidocaine Base for oil-based topical formulations.
-
Epinephrine Use: Adding a vasoconstrictor (epinephrine) slows absorption, prolongs duration, and reduces systemic toxicity risk.
-
Aspiration: Always aspirate before injection; avoid intravascular injection.
-
Topical Use: Rapidly absorbed from mucous membranes and damaged skin; calculate total dose when applying to large surfaces.
-
Stability: Amide bond is more stable than ester bond; provides long shelf life.
-
Storage: Store at room temperature in light-protected containers; keep away from strong oxidizing agents.
-
Personal Protective Equipment: Chemical-resistant gloves, safety goggles or face shield, protective clothing (lab coat), dust mask (N95/FFP2).
-
Hygiene: Wash hands thoroughly after handling; Do not eat, drink or smoke when using this product.
LEGAL DISCLAIMER:
The information provided in this document is based on our current knowledge and experience and is presented in good faith. However, as all conditions of use are beyond our control, it does not constitute a binding specification or guarantee. This Technical Data Sheet is for informational purposes only and does not constitute medical advice. Users are responsible for testing suitability for their own applications and for complying with all local, regional, and national regulations. For complete safety, storage, use, handling, waste, and regulatory compliance information, please refer to the official Safety Data Sheet (SDS/MSDS) provided by the manufacturer/supplier. Lidocaine is a pharmaceutical active ingredient; its use must be under the supervision of a healthcare professional.
